Abstract 1568P
Background
To increase the effectiveness of the treatment, radiotherapy (RT) is frequently combined with chemotherapy, immunotherapy, or radiosensitizer medications. Identifying a patient’s radiosensitivity can be important for determining patient’s therapy strategy. But there isn’t a reliable and pertinent radiation sensitivity prediction model for assessing radiation sensitivity. Here, we propose the cancer organoid-based platform for predicting the individual RT response evaluation and recurrence.
Methods
Eighteen Esophageal cancer biopsy tissues were dissociated to single cells and then disposed with BME on pillar plate (MBD co., Korea) to make the cancer organoids. After forming the organoids, these were exposed to radiation doses of 2, 4 and 8Gy. We are staining live organoid with calcein AM after radiation and obtain organoid viability. From viability, AUC (area under curve) and growth rate were calculated to predict patient’s radiation sensitivity. With these two variables, the patient's cancer stage score was also used to predict patient’s radiation sensitivity. CODRP (cancer organoid-based diagnosis reactivity prediction), radiosensitivity predication index, were calculated by patient’s AUC, growth rate, and cancer stage.
Results
Radiation sensitivity prediction model using each single-factor (patient’s AUC, growth rate and cancer stage) showed about 62% specificity, 72% sensitivity and positive predictive value (PPV) was 69%. However, when applying multi-factor model (CODRP), the specificity was 81.8%, the sensitivity was 85.7%, and the PPV was 90%. In the CODRP model, the radiation sensitive group showed 11.1% recurrence rate, while the radiation resistive group showed 72.7% recurrence rate. Therefore, there was a significant difference in recurrence-free survival rate between the sensitive group and the non-responder group based on the CODRP model.
Conclusions
Our proposed CODRP models using patient derived cancer organoid successfully predict clinical response of patient’s radiation treatment. Thus, this platform has promise as a novel prognostic indicator for people with esophageal cancer and can support precision treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21